CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$18.25M, compared with $23.53M a year earlier. Trailing-twelve-month net income was -$59.14M. Over 3 fiscal years it compounded at -44.1% a year.

Context

  • Net income amounted to 22.8% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$53.82M (+209.9%) for the fiscal year ending Dec 2026, a step up from the -154.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.25M-31.2% QoQ
Last fiscal yearDec 2025
-$17.37M-154.5% YoY
LTMMar 2026
-$59.14M-242.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-177.6%+10866.4%+11044.0 pp
1 year-154.5%+209.9%+364.4 pp
3-year CAGR-44.1%+46.4%+90.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(17.37M) USD
Year-over-year change
-154.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 net income of $59.14M is the 8th largest of the 10 companies compared; the peer median is $71.19M.
  • Its year-over-year change of -242.2% is the lowest of 9, against a peer median of +8.7%.
  • Net income amounts to 166.4% of revenue for CTMX, versus a peer median of 154.2%.
CTMX Competitors Peer median
Net Income for CTMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$309.06M +37.6%+32.1%275948.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M +220.5%+13.6%42.0%
STROSutro Biopharma, Inc.LTM Mar 2026$153.6M -37.4%+17.0%154.2%
ADCTADC Therapeutics S.A.LTM Mar 2026$136.99M -8.6%-3.2%173.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$81.74M -14.2%-13.0%589.8%
XNCRXencor, Inc.LTM Jun 2026$71.19M -60.8%+18.5%67.8%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M +26.1%-14.6%44.8%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$59.14M -242.2%-44.1%166.4%
ZYMEZymeworks Inc.LTM Sep 2026$43.31M +168.3%—16.3%
ADAGAdagene Inc.LTM Jun 2024$31.85M —-39.6%3904.3%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CTMX) $71.19M+8.7%+5.2%154.2%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.61M)(99.32M)(569K)31.87M(17.37M)
Depreciation & Amortization2.71M5.86M2.18M1.77M1.38M
Deferred Income Tax272K0000
Stock-Based Compensation13.17M13.13M8.56M7.67M6.3M
Change in Working Capital(54.7M)(30.65M)(62.51M)(126.42M)(68.58M)
Accounts Receivables8K(35.2M)32.55M329K1.09M
Inventory11.64M0000
Accounts Payables(139K)68K(1.43M)(297K)221K
Other Working Capital(66.21M)4.47M(93.64M)(126.45M)(69.89M)
Other Non-Cash Items3.13M13.33M(3.69M)(1.12M)2.68M
Operating Cash Flow(119.03M)(110.79M)(56.04M)(86.23M)(75.59M)
Capital Expenditures(1.61M)(1.74M)(840K)(310K)(220K)
Acquisitions (Net)(24.1M)0000
Purchases of Investments(99.9M)0(424.83M)(155.49M)(192.52M)
Sales of Investments124M100M275M255.5M133M
Other Investing Activities24.1M0000
Investing Cash Flow22.49M98.26M(150.67M)99.7M(59.74M)
Debt Repayment00000
Common Stock Issued107.71M648K30.23M6.91M110.45M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.5M00613K0
Financing Cash Flow110.21M648K30.23M7.52M110.45M
Effect of Forex Changes00000
Net Change in Cash13.67M(11.88M)(176.48M)20.99M(24.89M)
Free Cash Flow(120.64M)(112.53M)(56.88M)(86.54M)(75.81M)

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.